ClinicalTrials.gg
CompletedNCT07852585Updated Oct 1, 2026

Comparison of Pregnancy Outcomes in Primigravida Receiving Low-Dose Aspirin for the Prevention of Preeclampsia.

An interventional study of Low-dose aspirin and No-Aspirin in Preeclampsia, sponsored by Muhammad Aamir Latif. Completed at 1 site in Pakistan. Open to female participants aged 18 Years to 40 Years. Per ClinicalTrials.gov, last updated 2026-10-01.

Sponsored by Muhammad Aamir Latif · Not applicable, Interventional, and Prevention

How we know

From the registry’s dates

  • Registered 1 year 1 month after the study started (first participant enrolled Aug 2025, registered Sep 2026).
Updated Oct 1, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
160
Allocation
Randomized
Ages
18 Years to 40 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 52 studies testing aspirin in Pre-Eclampsia — 18 open to participants now, 22 under way, 5 of them phase 3. Aspirin · Pre-Eclampsia.

Enrollment
32nd of 52
160 · median 235
Started
2025
with 3 others
No phase
11 of 52
3 open now
Registered
52nd of 52
by date

Among the 52 studies testing aspirin in Pre-Eclampsia, this one is the 32nd largest by enrollment, is one of 4 that started in 2025, is one of 11 with no phase, and was the 52nd registered.

Pre-Eclampsia

918 studies on the registry are indexed under Pre-Eclampsia; 243 are open to participants now.

Browse Pre-Eclampsia studies →

Open to participants now

18 of the 52 studies testing aspirin in Pre-Eclampsia are open now, in 11 countries. Recruiting first, the newest first:

13 more — sign in →

By country, each count listing its studies:

All 18 open studies →

About aspirin

Aspirin: first FDA approval 1950 (PERCODAN), first EMA approval 2010. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 160 Pre-Eclampsia studies recruiting now, 79 (49%) set no upper age limit and 80 (50%) stop at 75 or younger; 18 take children under 18; 59 take healthy volunteers.

This study: 18 Years to 40 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 52 studies testing aspirin in Pre-Eclampsia, or all of them as a file.
02

Study summary

Local data on the effectiveness of low-dose aspirin in high-risk primigravida are limited. The present study was planned to compare pregnancy outcomes between high-risk primigravida receiving low-dose aspirin (75 mg/day) from 12 weeks of gestation and those not receiving aspirin.

Read the detailed description

Despite strong international evidence supporting low-dose aspirin for the prevention of preeclampsia, its use remains inconsistent in many developing countries, and evidence from local populations is limited. Further evaluation of its effectiveness among high-risk primigravida women may help inform appropriate clinical use and contribute to reducing adverse maternal and neonatal outcomes associated with preeclampsia.

03

Conditions studied

  • Preeclampsia

Browse trials for

04

Who can participate

Ages eligible
18 Years to 40 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Primigravida women
  • High-risk pregnancy
  • Aged 18-40 years
  • Singleton pregnancy
  • Gestational age ≤12 weeks

Exclusion criteria

Exclusion Criteria:

  • Women with pre-existing chronic hypertension
  • Renal disease
  • Diabetes mellitus
  • disease
  • Bleeding disorders
  • to aspirin
  • History of peptic ulcer disease
  • Those using aspirin or other antiplatelet drugs
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
160 participants (actual)

Study arms

  • Experimental
    Aspirin-Group

    Participants received low-dose aspirin (75 mg) once daily, starting at 12 weeks of gestation and continuing until 36 weeks of gestation or delivery, along with standard care.

    Drug: Low-dose aspirin · Other: No-Aspirin

  • Experimental
    No-Aspirin-Group

    Participants received standard antenatal care without aspirin.

    Other: No-Aspirin

Interventions

  • DrugAspirinStudies of AspirinAspirin pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Participants received low-dose aspirin (75 mg) once daily, starting at 12 weeks of gestation and continuing until 36 weeks of gestation or delivery, along with standard care.

  • OtherNo-Aspirin

    Participants received standard antenatal care without aspirin.

06

What researchers measure

Primary outcomes

  1. Preeclampsia

    The frequency of patients developing preeclampsia as new-onset hypertension after 20 weeks of gestation was noted.

    Time frame: After 24 weeks of the enrollment

  2. Placental abruption

    The frequency of patients with placental abruption.

    Time frame: After 24 weeks of the enrollment

  3. Preterm birth

    The frequency of neonates born before 37 completed weeks was noted.

    Time frame: At birth, after 24 weeks of the enrollment

  4. Low-birth-weight

    The frequency of low-birth-weight neonates, defined as a birth weight\<2.5 kg, was noted.

    Time frame: At birth, after 24 weeks of the enrollment

07

Study locations

1 site
  • Bahawal Victoria Hospital/Quaid-e-Azam Medical College
    Bahawalpur, Punjab Province 63100, Pakistan
08

References and documents

Individual participant data

Plan to share: No — Data can be shared on a reasonable request.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2025 to primary completion in Jun 2026, 10 months.

Of 172 non-industry interventional studies with no phase under Pre-Eclampsia, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 43. This study's 10 months is below that.

Counting every sponsor, half of 177 studies reached it within 24 months; a quarter within 10 and three quarters within 44.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 25, 2026
First posted
Oct 1, 2026
StartActual
Aug 1, 2025
Primary completionActual
Jun 30, 2026
CompletionActual
Jun 30, 2026
Last update
Oct 1, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Oct 1, 2026
Show all 1 update
  1. Oct 1, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07852585
Lead sponsor
Muhammad Aamir Latif
Responsible party
Muhammad Aamir Latif (Research Consultant, RESnTEC, Institute of Research) — Sponsor-investigator
First posted
Oct 1, 2026
Start date
Aug 1, 2025
Primary completion
Jun 30, 2026
Completion
Jun 30, 2026
Last update
Oct 1, 2026

Study contacts

Shamsun Nisa, FCPS
principal investigator · Bahawal Victoria Hospital/Quaid-e-Azam Medical College Bahawalpur

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Aspirin

Start the discussion